Question · Q3 2024
Cecilia Gong of JPMorgan Chase & Co. asked about the recovery seen in Q4, the confidence in reiterating guidance, and the reasons for the sequential decline in heart transplant revenue, specifically questioning the potential impact of NRP competition.
Answer
CEO Waleed Hassanein confirmed that market dynamics began to normalize in early October, supporting the reiterated guidance. He categorically denied any impact from competitive technologies like NRP on the heart volume decline, attributing it directly to a national volume downturn and noting TransMedics' DCD heart transplant share is approximately 70% and has grown.
Ask follow-up questions
Fintool can predict
TMDX's earnings beat/miss a week before the call